CONNAUGHT TRIPEDIA FIFTH DOSE POSTMARKETING SAFETY STUDIES TO FOLLOW FDA APPROVAL FOR PRIMARY SERIES; NVIC CALLS FOR REMOVAL OF WHOLE-CELL VACCINES
Executive Summary
Connaught will continue to collect safety data on Tripedia vaccinations through five doses in infants as part of its Phase IV commitments following the July 31 approval of the acellular pertussis vaccine for primary series immunizations.